Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alloreactive NK cells for MRD+ AML
NCT06885476Recruiting
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Open-label trial of alloreactive natural killer cells in acute myeloid leukemia (AML), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Safety of infusing alloreactive NK cells at 48 months. Started Jan 2021; status: recruiting.
02
Drugs
alloreactive natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06885476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885476.